Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | SDHA | P31040 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CALML3 | P27482 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2693170 | 1.00 | MAOA (0.51) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL4402288 | 1.00 | MAOA (0.51) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL4402134 | 0.93 | MAOA (0.51) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL4401289 | 0.92 | MAOA (0.51) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL4402117 | 0.91 | MAOA (0.49) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL2692823 | 0.91 | MAOA (0.49) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL2692826 | 0.91 | MAOA (0.49) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL2691287 | 0.90 | MAOA (0.55) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL2691289 | 0.90 | MAOA (0.55) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL2692411 | 0.89 | MAOA (0.48) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168797-B2 | Oxazolidinone derivative with difluorophenyl moiety, pharmaceutically acceptable salt thereof, preparation method thereof and antibiotic composition containing the same as an active ingredient | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-05-01 | — | — | US | claimed |
| WO-2010032901-A1 | NOVEL OXAZOLIDINONE DERIVATIVE WITH DIFLUOROPHENYL MOIETY, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND ANTIBIOTIC COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-03-25 | — | — | WO | claimed |
| US-20100069449-A1 | NOVEL OXAZOLIDINONE DERIVATIVE WITH DIFLUOROPHENYL MOIETY, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND ANTIBIOTIC COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE & TECHNOLOGY (KR) | 2010-03-18 | — | — | US | claimed |
| US-20100063117-A1 | Novel oxazolidinone derivative with difluorophenyl moiety, pharmaceutically acceptable salt thereof, preparation method thereof and antibiotic composition containing the same as an active ingredient | KOREA INSTITUTE OF SCIENCE & TECHNOLOGY (KR) | 2010-03-11 | — | — | US | claimed |
| US-8168797-B2 | Oxazolidinone derivative with difluorophenyl moiety, pharmaceutically acceptable salt thereof, preparation method thereof and antibiotic composition containing the same as an active ingredient | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-05-01 | — | — | US | disclosed |
| WO-2010032901-A1 | NOVEL OXAZOLIDINONE DERIVATIVE WITH DIFLUOROPHENYL MOIETY, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND ANTIBIOTIC COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069449-A1 | NOVEL OXAZOLIDINONE DERIVATIVE WITH DIFLUOROPHENYL MOIETY, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND ANTIBIOTIC COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE & TECHNOLOGY (KR) | 2010-03-18 | — | — | US | disclosed |
| US-20100063117-A1 | Novel oxazolidinone derivative with difluorophenyl moiety, pharmaceutically acceptable salt thereof, preparation method thereof and antibiotic composition containing the same as an active ingredient | KOREA INSTITUTE OF SCIENCE & TECHNOLOGY (KR) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063117-A1 | Novel oxazolidinone derivative with difluorophenyl moiety, pharmaceutically acceptable salt thereof, preparation method thereof and antibiotic composition containing the same as an active ingredient | VRK1, ALPI, VRK2 | MAOA 2024/4885MAOB 1898/4885PTGS1 4375/4885 |
| US-20100069449-A1 | NOVEL OXAZOLIDINONE DERIVATIVE WITH DIFLUOROPHENYL MOIETY, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND ANTIBIOTIC COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | VRK1, ALPI, VRK2 | MAOA 2024/4885MAOB 1898/4885PTGS1 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.